ASCO 2023 | Safety and efficacy of obe-cel in R/R adult B-ALL: results of the pivotal FELIX study
Claire Roddie, MD, PhD, University College London Cancer Institute, London, UK, comments on the results from the Phase Ib/II FELIX study (NCT04404660), which is evaluating the safety and efficacy of obecabtagene autoleucel (obe-cel), a fast-off rate CD19 CAR, in patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). Dr Roddie shares some insights into the design and rationale of this trial, as well as the demographics of the patient population. Preliminary results demonstrate that 76% of patients achieved a complete response, with 97% of these responses being measurable residual disease (MRD) negative. Obe-cel has also demonstrated a promising toxicity profile and appears to be well tolerated in this group of high-risk patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
